Company news: Edelman, Pfizer, Publicis, Lippincott

Share this article:

Dan Edelman, founder of the eponymous PR firm, a major player in healthcare PR, has died. The former reporter founded his agency in Chicago 61 years ago, reported PRWeek. He is survived by his wife, Ruth, a daughter, Renee, sons Richard and John and granddaughters Margot, Tory, and Amanda.

Pfizer's Geno Germano, head of specialty and oncology, told Bloomberg that Pfizer would "probably evolve to two" divisions, fueling speculation that the firm might follow Abbott Labs' lead and split. Spokeswoman Joan Campion dismissed the report as speculation spiked with dated comments from analysts. “There is no new news here,” she told MM&M, noting that the idea of breaking up the company surfaces every quarter, and adding that nothing in the business structure has changed. Germano was quoted as saying the company will probably “evolve to two, where there's the innovative business and the value business.” Pfizer offloaded its nutrition business on Nestle in early 2012, and is expected to spin off its animal business under the name Zoetis this year.


Industry vet Mark Stevens has been hired on as SVP, commercial solutions for Publicis Touchpoint Solutions. Stevens, who has held posts with Wolters Kluwer, Bristol-Myers Squibb, Pfizer and Sanofi, will be in charge of enhancing customer-directed tech and tools.

Lippincott's latest Nursing Advisor includes a pill identifier and drug interactions tool that can help nurses troubleshoot patient medications. The tool means nurses will be able to identify what a patient is taking by entering variables such as a pill's color, shape, score or dose. Nurses will also be able to cross-reference medications with multiple drugs, patient allergies, patient gender and diseases, among other factors.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.